TICKERNERD
Menu
ZBHZBHHealthcare · Medical Devices

ZBH Stock Forecast: Zimmer Biomet Holdings, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$95
+1.18% on the day

The 27 Wall Street analysts covering Zimmer Biomet Holdings, Inc. hold a median 12-month price target of $106 — +11.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 19 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$18.2B
Ticker Nerd rank
91 / 100
Median analyst target
$106
Analysts covering
27
Revenue$2.2B+4.8% y/y
Operating income$374.0M
Net income$199.6M
Free cash flow$331.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.0%
1M
−3.8%
YTD
+6.6%
1Y
−3.8%
From 52W high
−7.6%
From 52W low
+20.1%
$79
$103
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZBH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zimmer Biomet Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
91 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
95
Volatility
93
Issuance
91
Revisions
83
Accruals
69
Quality
60
Growth
60
Momentum
55
Size
10

Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (55): The shares have been drifting down relative to others.

Size (10): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ZBH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZBH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$80$90$100$110$120$130Oct 25Jan 26Apr 26Jul 26ZBHHigh $130Median $106Low $93

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says27 analysts
9 Buy18 Hold0 Sell
Low $93Median $106High $130

The green dot is the last close — the median target sits +11.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
10 Aug 2026Canaccord GenuityMaintainsHold$83 → $100
7 Aug 2026Truist SecuritiesMaintainsHold$92 → $106
6 Aug 2026BernsteinMaintainsMarket Perform$91 → $93
6 Aug 2026RBC CapitalMaintainsOutperform$101 → $110
6 Aug 2026StifelMaintainsBuy$105 → $110
28 July 2026UBSAssumesBuy$89 → $115
9 July 2026BMO CapitalInitiatesMarket Perform$95
9 July 2026BMO CapitalInitiatesMarket Perform—
6 July 2026Evercore ISI GroupMaintainsOutperform$120 → $110
6 July 2026Evercore ISI GroupMaintainsOutperform—
28 May 2026CitigroupMaintainsNeutral—
29 Apr 2026BarclaysMaintainsUnderweight—
29 Apr 2026CitigroupMaintainsNeutral—
29 Apr 2026CitizensMaintainsMarket Outperform—
29 Apr 2026JP MorganMaintainsNeutral—
29 Apr 2026StifelMaintainsBuy—
29 Apr 2026Truist SecuritiesReiteratesHold—
29 Apr 2026Wells FargoMaintainsEqual-Weight—
13 Apr 2026Leerink PartnersInitiatesMarket Perform—
23 Mar 2026BTIGDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZBH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ZBH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Zimmer Biomet Holdings, Inc. returned −3.8% against +16.3% for the S&P 500, dividends included.

ZBH vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Oct 25Jan 26Apr 26Jul 26ZBHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ZBH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.6%
Analysts raising
22
Analysts cutting
1
Fundamentals

Zimmer Biomet Holdings, Inc. (ZBH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
23.1×

Cheaper than 32% of US stocks

Price / sales
2.1×

Cheaper than 51% of US stocks

Price / book
1.4×

Cheaper than 56% of US stocks

EV / EBITDA
10.0×

Cheaper than 38% of US stocks

Growth & margins
Revenue growth (YoY)
4.8%

Higher than 38% of US stocks

Earnings growth (YoY)
29.8%

Higher than 65% of US stocks

Gross margin
70.8%

Higher than 83% of US stocks

Operating margin
18.0%

Higher than 76% of US stocks

Net margin
9.5%

Higher than 69% of US stocks

Returns & dividend
Return on equity
6.4%

Higher than 55% of US stocks

Return on assets
3.9%

Higher than 70% of US stocks

Dividend yield
1.0%

Higher than 22% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Zimmer Biomet Holdings, Inc. (ZBH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zimmer Biomet Holdings, Inc. has a market value of $18.2B and an enterprise value of $25.3B.

  • Revenue in the twelve months to 30 June 2026: $8.5B. The latest quarter grew 4.8% year on year.

  • Net income over the same four quarters: $807.0M, a 9.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $1.4B.

  • Zimmer Biomet Holdings, Inc. spent $750.8M on share buybacks and $188.4M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 190.6M.

  • Trailing P/E: 23.1×; forward P/E: 10.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.01%, paying out 23% of earnings.

  • Zimmer Biomet Holdings, Inc. employs 17,000 people — $501K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

ZBH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ZBHZimmer Biomet Holdings, Inc.$18.2B
91
STESTERIS Plc (Ireland)$20.0B
83
PENPenumbra, Inc.$12.5B
75
GEHCGE Healthcare Technologies, Inc.$29.2B
62
DXCMDexCom, Inc.$34.5B
98
BIOBio-Rad Laboratories, Inc.$10.1B
90
TXG10X Genomics, Inc.$10.0B
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Zimmer Biomet Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ZBH news & analysis

Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock

Zacks Investment Research · 17 Sept 2026positive

Zacks Investment Research published an article explaining why Zimmer Biomet (ZBH) is considered a strong value stock, highlighting the Zacks Style Scores feature of its Zacks Premium research service as a tool that helps investors identify strong stocks.

Why it matters — A ZBH watcher would care because this report indicates analysts view Zimmer Biomet favorably on valuation metrics within the Zacks research framework.

Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation

PRNewsWire · 8 Sept 2026positive

Gary Campbell has been promoted to President, Americas at Zimmer Biomet, with Brian Hatcher promoted to President of Recon, S.E.T., CMFT, Neuro and Biosurgery, and Bradley Kessler promoted to President of Americas – Robotics, Technology and Data. These leadership changes are part of the company's effort to accelerate its commercial transformation.

Why it matters — Zimmer Biomet watchers would care because new leadership in the Americas and technology/robotics divisions signals a strategic push to drive commercial growth and transformation.

Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report?

Zacks Investment Research · 4 Sept 2026neutral

Zimmer Biomet (ZBH) reported earnings 30 days ago, and its stock has risen 1.8% since that report. Zacks examines what may be next for the company's shares following the earnings release.

Why it matters — ZBH watchers would care because the article assesses the company's recent performance since its last earnings report and looks ahead to what might follow.

Zimmer Biomet - Showing Signs Of Life

Seeking Alpha · 1 Sept 2026positive

Zimmer Biomet is showing signs of structural constant currency sales growth, driven by transformation efforts, R&D, and M&A. While earnings growth is currently lagging behind sales growth, the expectation is that it should soon catch up.

Why it matters — A ZBH watcher would care because the report indicates that the company's sales growth is improving, while earnings are expected to follow suit in the near term.

Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term

Zacks Investment Research · 31 Aug 2026positive

Zacks Investment Research highlights Zimmer Biomet (ZBH) as a top value stock for the long term, using its Zacks Style Scores to identify top-rated stocks based on investing style. The article points to ZBH as well-positioned among value-oriented stocks.

Why it matters — A ZBH watcher would care because the piece affirms that the stock is regarded as a strong long-term value pick according to Zacks' screening methodology.

FAQ

Frequently asked questions about ZBH stock

What is the ZBH stock price forecast for 2026-2027?

The 27 Wall Street analysts covering Zimmer Biomet Holdings, Inc. have a median 12-month price target of $106, with estimates ranging from $93 to $130. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZBH stock a buy right now?

Of the 27 analysts covering Zimmer Biomet Holdings, Inc., 9 rate it a Buy, 18 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zimmer Biomet Holdings, Inc. 91 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZBH?

As at 19 Sept 2026, Zimmer Biomet Holdings, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).

Will ZBH stock go up?

No one can know that. What the data says: the median 12-month target from 27 analysts implies +11.2% from the last close, and Ticker Nerd's factor model ranks Zimmer Biomet Holdings, Inc. 91 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZBH stock forecast for 2030?

No analyst covering Zimmer Biomet Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZBH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $93 to $130 over the next 12 months.

How has ZBH stock performed over the past year?

Zimmer Biomet Holdings, Inc. returned -3.8% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zimmer Biomet Holdings, Inc. do?

Zimmer Biomet Holdings Inc. is a global medical technology company focused on musculoskeletal healthcare.

What is the latest news on ZBH?

The most recent item we track (Zacks Investment Research, 17 Sept 2026): "Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock". Zacks Investment Research published an article explaining why Zimmer Biomet (ZBH) is considered a strong value stock, highlighting the Zacks Style Scores feature of its Zacks Premium research service as a tool that helps investors identify strong stocks.

Company

About Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings Inc. is a global medical technology company focused on musculoskeletal healthcare. The company designs, manufactures, and markets orthopedic reconstructive products, including knee and hip systems, along with sports medicine, biologics, extremities, and trauma solutions. Its portfolio also includes craniomaxillofacial and thoracic products, office-based technologies, bone cement, surgical instruments, and integrated digital and robotic technologies used in orthopedic procedures. Zimmer Biomet serves healthcare professionals, hospitals, and surgical centers by providing products that support the treatment of bone, joint, and soft-tissue disorders. Headquartered in Warsaw, Indiana, Zimmer Biomet plays an important role in orthopedic care across major markets worldwide.

CEO Mr. Ivan Tornos · 17,000 employees · United States · https://www.zimmerbiomet.com